Lesson
Read Parkinson Disease as a Circuit Disorder
Loss of dopaminergic neurons in the substantia nigra pars compacta changes basal ganglia output and makes movement smaller, slower, and harder to initiate.
- Substantia nigra
- Striatum
- Dopamine
- Bradykinesia
- Circuit balance
motor circuit
Follow dopamine, timing, function, and treatment burden through one connected circuit.
Trace the signal
Nigrostriatal dopamine normally supports movement through coordinated direct and indirect basal ganglia pathways. Dopamine depletion increases inhibitory output to thalamocortical motor networks.
Make bradykinesia central
Bradykinesia is required for clinical parkinsonism and appears as decrementing repetitive movement, reduced arm swing, hypomimia, soft speech, small handwriting, and difficulty initiating movement.
Separate symptomatic benefit from disease modification
Levodopa and other dopaminergic therapies restore signaling enough to improve symptoms. They do not replace lost neurons or prove a neuroprotective effect.
See beyond dopamine
Cholinergic, noradrenergic, serotonergic, autonomic, sleep, and cortical systems contribute to symptoms that may respond poorly to levodopa.
Quick check
Lesson
Diagnose the Syndrome Before Naming the Disease
Parkinson disease is diagnosed clinically from parkinsonism, supportive features, exclusion of alternatives, and longitudinal course.
- Bradykinesia
- Rest tremor
- Rigidity
- Red flags
- Mimics
diagnosis
Follow dopamine, timing, function, and treatment burden through one connected circuit.
Define parkinsonism
Bradykinesia plus rest tremor or rigidity establishes the motor syndrome. Postural instability often appears later and should not be required at onset.
Use asymmetry and evolution
Typical disease often begins asymmetrically and progresses gradually. A clear and sustained levodopa response supports the diagnosis but is not a standalone test.
Look for alternatives
Early severe falls, rapid progression, prominent early autonomic failure, vertical gaze palsy, cerebellar signs, pyramidal findings, symmetric drug-linked onset, or poor levodopa response should prompt reassessment.
Review causative medicines
Metoclopramide, prochlorperazine, haloperidol, risperidone, paliperidone, and other dopamine blockers can cause or worsen parkinsonism. Timing and persistence after withdrawal matter.
Quick check
Lesson
Measure the Disease Outside the Motor Examination
Nonmotor symptoms can precede diagnosis, drive quality of life, and change medication safety.
- Autonomic
- Sleep
- Mood
- Cognition
- Pain
nonmotor system
Follow dopamine, timing, function, and treatment burden through one connected circuit.
Recognize prodromal patterns
Anosmia, constipation, REM sleep behavior disorder, depression, and autonomic change can precede recognizable parkinsonism, but none is diagnostic alone.
Ask directly
Screen orthostatic symptoms, urinary dysfunction, sexual dysfunction, drooling, swallowing, sleepiness, hallucinations, impulse-control behavior, pain, anxiety, depression, and cognition.
Separate disease from treatment
Hallucination, somnolence, edema, orthostasis, nausea, dyskinesia, and compulsive behavior may reflect medication, disease, or both. Timing against dose changes is informative.
Measure function
Track falls, freezing, driving, work, self-care, meal preparation, medication administration, communication, caregiver strain, and participation.
Quick check
Lesson
Use Levodopa as a Precisely Delivered Precursor
Levodopa crosses the blood-brain barrier and is converted to dopamine, while carbidopa reduces peripheral conversion and improves central delivery and tolerability.
- Levodopa
- Carbidopa
- Decarboxylase
- Blood-brain barrier
- Formulation
levodopa system
Follow dopamine, timing, function, and treatment burden through one connected circuit.
Explain the combination
Dopamine itself does not cross the blood-brain barrier effectively. Levodopa does. Peripheral aromatic L-amino-acid decarboxylase would consume much of it without carbidopa.
Use current first-line reasoning
AAN recommends levodopa as the preferred initial dopaminergic therapy for patients who seek motor treatment. NICE offers levodopa when motor symptoms affect quality of life.
Start low and observe
Titrate to meaningful function while monitoring nausea, orthostasis, sleepiness, hallucinations, dyskinesia, and impulse-control behavior. Older or cognitively vulnerable patients often tolerate levodopa better than dopamine agonists.
Respect product differences
Immediate release and extended-release tablets or capsules are not automatically interchangeable. Use product-specific conversion and administration instructions.
Quick check
Lesson
Turn a Dose Diary Into a Pharmacokinetic Map
Wearing off, delayed on, dose failure, freezing, off dystonia, and peak-dose dyskinesia require different changes.
- On
- Off
- Latency
- Dyskinesia
- Meal timing
dose timing
Follow dopamine, timing, function, and treatment burden through one connected circuit.
Define predictable wearing off
Symptoms recurring before the next scheduled dose suggest shortening duration. Options include dose-interval adjustment, formulation change, or an adjunct that extends levodopa effect.
Investigate delayed on
Delayed gastric emptying, constipation, protein competition, iron, and meal timing can delay or prevent absorption. More levodopa is not always the first answer.
Map dyskinesia
Peak-dose dyskinesia occurs during high exposure, diphasic dyskinesia during rising and falling concentrations, and off dystonia during low exposure. The pattern directs treatment.
Protect nutrition
A consistent relation to meals is useful. Separating levodopa from protein can help selected fluctuations, but protein redistribution should not create malnutrition or frailty.
Quick check
Lesson
Choose an Adjunct for a Defined Failure Mode
Dopamine agonists, MAO-B inhibitors, COMT inhibitors, amantadine, istradefylline, and anticholinergics differ in target and burden.
- Dopamine agonist
- MAO-B
- COMT
- Amantadine
- Istradefylline
adjunct map
Follow dopamine, timing, function, and treatment burden through one connected circuit.
Limit dopamine agonist burden
Pramipexole, ropinirole, and rotigotine can reduce symptoms or off time but increase hallucination, orthostasis, edema, sudden sleep, and impulse-control risk. Renal function matters especially for pramipexole.
Extend dopamine metabolism carefully
Rasagiline, selegiline, and safinamide inhibit MAO-B. Entacapone, opicapone, and tolcapone inhibit COMT and are used with levodopa. Both strategies can unmask dyskinesia.
Use amantadine for the right target
Amantadine is useful for dyskinesia and selected off time. Renal dosing and monitoring for hallucinations, edema, orthostasis, and livedo reticularis are essential.
Keep anticholinergics narrow
Benztropine or trihexyphenidyl may help selected tremor in younger patients but can worsen cognition, constipation, urinary retention, dry mouth, vision, and falls.
Quick check
Lesson
Treat Fluctuation Without Chasing Every Movement
Motor complications emerge from disease progression, levodopa pharmacokinetics, dose pattern, meals, sleep, stress, and medication adherence.
- Wearing off
- Peak dose
- Freezing
- Rescue
- Diary
dyskinesia
Follow dopamine, timing, function, and treatment burden through one connected circuit.
Reduce peak burden
Smaller or redistributed levodopa doses, formulation changes, reduction of an amplifying adjunct, or amantadine may reduce peak-dose dyskinesia.
Extend on time
COMT inhibitors, MAO-B inhibitors, selected dopamine agonists, istradefylline, or continuous delivery can reduce off time, but each can increase dyskinesia or other toxicity.
Use rescue deliberately
Inhaled levodopa and subcutaneous apomorphine treat selected off episodes. They require preserved ability to recognize and administer rescue and do not replace baseline optimization.
Avoid dangerous antiemetic pairing
Apomorphine is contraindicated with 5-HT3 antagonists because severe hypotension and loss of consciousness can occur. Product availability and instructions must be verified.
Quick check
Lesson
Escalate Delivery When Oral Timing Becomes the Disease
Advanced therapy can smooth dopaminergic exposure or modulate motor circuitry when optimized oral treatment no longer controls disabling fluctuations.
- VYALEV
- Intestinal gel
- Apomorphine
- DBS
- Selection
advanced therapy
Follow dopamine, timing, function, and treatment burden through one connected circuit.
Know the new continuous option
VYALEV, approved by FDA in 2024, delivers foscarbidopa and foslevodopa by continuous subcutaneous infusion for motor fluctuations in adults with advanced Parkinson disease.
Compare delivery burden
Subcutaneous infusion avoids a jejunal tube but creates pump, cannula, skin, training, and infection responsibilities. Intestinal gel has procedure and device burdens. Continuous apomorphine availability varies by setting.
Select DBS by phenotype
Deep brain stimulation can help levodopa-responsive motor fluctuations, tremor, and dyskinesia. Cognition, psychiatric stability, gait, speech, goals, target selection, and surgical risk matter.
Preserve a backup plan
Device interruption can rapidly remove dopaminergic coverage. Patients and caregivers need supplies, troubleshooting, emergency contacts, and an oral rescue or conversion plan when appropriate.
Quick check
Lesson
Protect Reality Without Blocking Movement
Hallucinations and delusions require a search for delirium, infection, medication burden, sleep disruption, sensory impairment, and disease progression.
- Delirium
- Deprescribing
- Pimavanserin
- Clozapine
- D2 blockade
psychosis
Follow dopamine, timing, function, and treatment burden through one connected circuit.
Start with urgency
Acute inattention, fluctuation, fever, dehydration, urinary symptoms, hypoxia, pain, or a recent medication change suggests delirium and requires cause-directed care.
Reduce burden in a sequence
When safe, reassess anticholinergics, amantadine, MAO-B inhibitors, dopamine agonists, and other contributors while preserving necessary levodopa and watching motor decline.
Use current labeled therapy
Pimavanserin is FDA approved for hallucinations and delusions associated with Parkinson disease psychosis. It has mortality, QT, CYP3A4, and patient-specific safety considerations.
Avoid routine motor worsening
Haloperidol, risperidone, and many D2-blocking antipsychotics can markedly worsen parkinsonism. Clozapine has efficacy with blood monitoring, while quetiapine is used selectively despite less certain efficacy.
Quick check
Lesson
Treat the Nonmotor Systems That Determine Independence
Orthostasis, constipation, swallowing, drooling, urinary symptoms, sleep, mood, and cognition often determine daily safety more than tremor.
- Orthostasis
- Constipation
- Dysphagia
- Sleep
- Mood
autonomic
Follow dopamine, timing, function, and treatment burden through one connected circuit.
Measure orthostasis correctly
Record supine and standing blood pressure with symptoms and timing. Review dehydration, meals, heat, antihypertensives, dopaminergic drugs, and other contributors before adding medication.
Protect against supine hypertension
Compression, hydration, salt when appropriate, head-of-bed elevation, and selected agents such as droxidopa or midodrine require individualized cardiovascular and supine-pressure review.
Treat swallowing as medication safety
Dysphagia can cause aspiration, weight loss, and missed or altered doses. Speech-language pathology, nutrition, dosage-form review, and timing are connected interventions.
Coordinate neuropsychiatric care
Depression, anxiety, apathy, sleepiness, REM sleep behavior disorder, and cognitive change need diagnosis-specific treatment rather than reflexive dopaminergic escalation.
Quick check
Lesson
Treat Parkinson Medicines as Time Critical
Delayed, omitted, crushed, substituted, or abruptly stopped Parkinson medicines can rapidly cause immobility, aspiration, delirium, and a hyperpyrexia syndrome.
- Medication reconciliation
- Exact timing
- Dopamine blockers
- Withdrawal
- Swallowing
hospital safety
Follow dopamine, timing, function, and treatment burden through one connected circuit.
Record the real schedule
Parkinson regimens may use individualized times rather than standard medication rounds. Record product, strength, formulation, exact time, meals, rescue use, and device settings.
Avoid hidden dopamine blockers
Metoclopramide, prochlorperazine, promethazine, droperidol, haloperidol, and many antipsychotics can worsen parkinsonism. Select nausea and behavior treatment with specialist-aware reasoning.
Plan before nothing by mouth
Swallowing failure, surgery, bowel dysfunction, and device interruption require early neurology, pharmacy, anesthesia, and nutrition coordination. Do not wait until multiple doses are missed.
Recognize withdrawal emergency
Abrupt dopaminergic withdrawal can cause fever, severe rigidity, altered mental status, autonomic instability, and elevated creatine kinase. Restore therapy when appropriate and provide emergency care.
Quick check
Lesson
Build Care Around the Life the Patient Is Protecting
The best regimen improves meaningful on time and participation without unacceptable dyskinesia, hallucination, sleepiness, falls, or treatment burden.
- Exercise
- Therapy
- Caregiver
- Goals
- Follow-up
recovery
Follow dopamine, timing, function, and treatment burden through one connected circuit.
Prescribe movement
Regular aerobic, resistance, balance, cueing, and task-specific exercise can support mobility and function. Physical therapy should address freezing, gait, transfers, and falls.
Protect communication and eating
Speech therapy can address voice and swallowing. Occupational therapy can adapt dressing, writing, driving, work, home safety, and medication routines.
Include the care partner
Care partners may first recognize hallucinations, compulsive behavior, sleep attacks, cognition, falls, or dose failure. Their health, capacity, and goals also require support.
Review the whole outcome
Track on and off time, troublesome dyskinesia, nonmotor symptoms, falls, driving, nutrition, sleep, mood, cognition, device burden, adherence, and patient-defined participation.
Quick check
Module test
Check the connections.
Each attempt draws 10 questions from the complete 100 question bank.
Each attempt draws a fresh set and rearranges the answer choices.
References
Current clinical foundation.
Lecture material was synthesized with the following contemporary guidance. Verify local policy and current guidance before applying clinical information.
- RxPrep 2023 Parkinson Disease chapter, printed pages 876 through 880
- AAN: Dopaminergic Therapy for Motor Symptoms in Early Parkinson Disease
- NICE NG71: Parkinson's disease in adults
- FDA: SINEMET prescribing information, 2026
- FDA: VYALEV prescribing information, 2024
- FDA: NUPLAZID prescribing information, 2025